Skip to content
10-Q

Quarterly Report

VIKING THERAPEUTICS, INC. VKTX

0000950170-24-116708

← back to feed
Filed
Oct 23, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2024 · Oct 15, 2024 111.44M sh
Cash And Equivalents Q3 2024 · Sep 30, 2024 $50.35M
Cash And Equivalents Q3 2024 · Dec 31, 2023 $55.52M
Stockholders Equity Q3 2024 · Sep 30, 2024 $911.45M
Stockholders Equity Q3 2024 · Dec 31, 2023 $348.42M
Current Liabilities Q3 2024 · Sep 30, 2024 $25.69M
Current Liabilities Q3 2024 · Dec 31, 2023 $19.14M
Total Liabilities Q3 2024 · Sep 30, 2024 $26.44M
Total Liabilities Q3 2024 · Dec 31, 2023 $20.07M
Current Assets Q3 2024 · Sep 30, 2024 $936.65M
Current Assets Q3 2024 · Dec 31, 2023 $367.23M
Total Assets Q3 2024 · Sep 30, 2024 $937.89M
Total Assets Q3 2024 · Dec 31, 2023 $368.49M
Shares Diluted Q3 2024 · Sep 30, 2023 99.85M sh
Shares Diluted Q3 2024 · Sep 30, 2023 92.48M sh
Operating Cash Flow Q3 2024 · Sep 30, 2023 −$55.74M
Eps Diluted Q3 2024 · Sep 30, 2023 −$0.23
Eps Diluted Q3 2024 · Sep 30, 2023 −$0.66
Eps Basic Q3 2024 · Sep 30, 2023 −$0.23
Eps Basic Q3 2024 · Sep 30, 2023 −$0.66
Sga Expense Q3 2024 · Sep 30, 2023 $8.89M
Sga Expense Q3 2024 · Sep 30, 2023 $28.24M
Rd Expense Q3 2024 · Sep 30, 2023 $18.38M
Rd Expense Q3 2024 · Sep 30, 2023 $43.3M
Net Income Q3 2024 · Sep 30, 2023 −$22.53M
Net Income Q3 2024 · Sep 30, 2023 −$61.29M
Operating Income Q3 2024 · Sep 30, 2023 −$27.27M
Operating Income Q3 2024 · Sep 30, 2023 −$71.54M
Revenue Q3 2024 · Sep 30, 2023 $0
Revenue Q3 2024 · Sep 30, 2023 $0